Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (NCT04626024)

🧪 Interventions in This Study

• Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (4 Sites)

• Baylor College of Medicine- McNair Campus — Houston, Texas
• Ben Taub General Hospital — Houston, Texas
• CHI St. Luke's Health Baylor College of Medicine Medical Center — Houston, Texas
• Harris Health System- Smith Clinic — Houston, Texas

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Myeloid Leukemia

• Selumetinib and Azacitidine in High Risk Chronic Blood Cancers — Chicago, Illinois
• A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia — New York, New York
• Study of Olverembatinib (HQP1351) in Patients With CP-CML — Houston, Texas
• Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase — Houston, Texas
• Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. — Houston, Texas

Explore by condition: All Chronic Myeloid Leukemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.